Evolus, Inc.

NasdaqGM:EOLS Rapport sur les actions

Capitalisation boursière : US$1.1b

Evolus Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

David Moatazedi

Directeur général

US$11.2m

Rémunération totale

Pourcentage du salaire du PDG6.1%
Durée du mandat du directeur général6.5yrs
Propriété du PDGn/a
Durée moyenne d'occupation des postes de direction3yrs
Durée moyenne du mandat des membres du conseil d'administration6.5yrs

Mises à jour récentes de la gestion

Recent updates

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Oct 22
Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Evolus Continues To Make Progress

Aug 02

Evolus, Inc. (NASDAQ:EOLS) Looks Just Right With A 32% Price Jump

Aug 02
Evolus, Inc. (NASDAQ:EOLS) Looks Just Right With A 32% Price Jump

Evolus (NASDAQ:EOLS) Is Making Moderate Use Of Debt

Jul 13
Evolus (NASDAQ:EOLS) Is Making Moderate Use Of Debt

Evolus: Chiseling Away At The Aesthetic Market

May 22

Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

May 10
Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028

Mar 20

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 10
The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Jan 18
Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Jan 18
Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Jun 16
Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Nov 06
Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Evolus concludes certain royalty payments related to settlement of IP rights dispute

Sep 21

Evolus: Turning That Frown Upside Down

Sep 11

Evolus appoints Experian's exec as CFO

Aug 30

Is Evolus (NASDAQ:EOLS) Using Too Much Debt?

Aug 04
Is Evolus (NASDAQ:EOLS) Using Too Much Debt?

Evolus Q2 2022 Earnings Preview

Aug 01

Is Evolus (NASDAQ:EOLS) Using Debt Sensibly?

Mar 21
Is Evolus (NASDAQ:EOLS) Using Debt Sensibly?

Analyse de la rémunération des PDG

Comment la rémunération de David Moatazedi a-t-elle évolué par rapport aux bénéfices de Evolus?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 30 2024n/an/a

-US$55m

Jun 30 2024n/an/a

-US$53m

Mar 31 2024n/an/a

-US$60m

Dec 31 2023US$11mUS$688k

-US$62m

Sep 30 2023n/an/a

-US$63m

Jun 30 2023n/an/a

-US$66m

Mar 31 2023n/an/a

-US$72m

Dec 31 2022US$4mUS$597k

-US$74m

Sep 30 2022n/an/a

-US$79m

Jun 30 2022n/an/a

-US$79m

Mar 31 2022n/an/a

-US$71m

Dec 31 2021US$4mUS$572k

-US$47m

Sep 30 2021n/an/a

-US$139m

Jun 30 2021n/an/a

-US$131m

Mar 31 2021n/an/a

-US$137m

Dec 31 2020US$3mUS$527k

-US$163m

Sep 30 2020n/an/a

-US$67m

Jun 30 2020n/an/a

-US$82m

Mar 31 2020n/an/a

-US$99m

Dec 31 2019US$2mUS$550k

-US$90m

Sep 30 2019n/an/a

-US$88m

Jun 30 2019n/an/a

-US$73m

Mar 31 2019n/an/a

-US$52m

Dec 31 2018US$6mUS$362k

-US$47m

Rémunération vs marché: La rémunération totale de David ($USD 11.24M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 3.18M ).

Rémunération et revenus: La rémunération de David a augmenté alors que l'entreprise n'est pas rentable.


PDG

David Moatazedi (46 yo)

6.5yrs

Titularisation

US$11,240,447

Compensation

Mr. David Moatazedi is Independent Director at Biomerica Inc. from December 07, 2022. He has been the President, Chief Executive Officer and Director of Evolus, Inc. since joining it on May 6, 2018. Mr. Mo...


Équipe de direction

NomPositionTitularisationCompensationPropriété
David Moatazedi
President6.5yrsUS$11.24mpas de données
Sandra Beaver
Chief Financial Officer2.2yrsUS$2.46m0.052%
$ 551.2k
Rui Avelar
Chief Medical Officer and Head of Research & Development10.8yrsUS$2.93m0.31%
$ 3.3m
Nareg Sagherian
Head of Global Investor Relations & Corporate Communicationsless than a yearpas de donnéespas de données
Jeffrey Plumer
General Counselno datapas de donnéespas de données
Kurt Knab
Vice President of Sales6.1yrspas de donnéespas de données
Tomoko Yamagishi-Dressler
Chief Marketing Officer1.3yrspas de données0.016%
$ 171.6k
Jessica Novak
Senior Vice President of Human Resources3yrspas de donnéespas de données

3.0yrs

Durée moyenne de l'emploi

46yo

Âge moyen

Gestion expérimentée: L'équipe de direction de EOLS est considérée comme expérimentée (ancienneté moyenne 3 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
David Moatazedi
President6.5yrsUS$11.24mpas de données
David Gill
Independent Director6.8yrsUS$256.03k0.044%
$ 462.3k
Simone Blank
Director6.8yrsUS$235.03k0.87%
$ 9.2m
Albert White
Independent Directorless than a yearpas de donnéespas de données
Vikram Malik
Chairman of the Board6.8yrsUS$271.03k0.37%
$ 4.0m
Karah Parschauer
Independent Director5.3yrsUS$249.03k0.050%
$ 525.2k
Brady Stewart
Independent Director2.8yrsUS$222.03k0.071%
$ 753.1k

6.5yrs

Durée moyenne de l'emploi

54yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de EOLS sont considérés comme expérimentés (ancienneté moyenne 6.5 ans).